Prognostic value of bone- and vascular-derived molecular biomarkers in hemodialysis and renal transplant patients: A systematic review and meta-analysis

Nephrology Dialysis Transplantation

Volumn 32, Issue 9, 2017, Pages 1566-1578

  Pichler, Gernot ^a,b,c   Haller, Maria C ^c,d,e   Kainz, Alexander ^c   Wolf, Myles ^f   Redon, Josep ^a,g   Oberbauer, Rainer ^c  

^a Instituto Universitario IVI INCLIVA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d ELISABETHINEN HOSPITAL   (Austria)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

^f NORTHWESTERN UNIVERSITY   (United States)

^g Instituto de Salud Carlos III   (Spain)

Author keywords

biomarkers; ESRD; FGF23; meta analysis; systematic review

Indexed keywords

BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOGENIC PROTEIN 1; OSTEOPONTIN; OSTEOPROTEGERIN;

ALL CAUSE MORTALITY; ARTICLE; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; DATA EXTRACTION; FOLLOW UP; HEMODIALYSIS; HUMAN; KIDNEY TRANSPLANTATION; META ANALYSIS (TOPIC); PRIORITY JOURNAL; PROGNOSIS; SYSTEMATIC REVIEW; BONE DISEASE; COMPLICATION; KIDNEY DISEASE; META ANALYSIS; METABOLISM; MORTALITY; SURVIVAL RATE;

BIOMARKERS; BONE DISEASES; CARDIOVASCULAR DISEASES; HUMANS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; PROGNOSIS; RENAL DIALYSIS; SURVIVAL RATE;

EID: 85029816537     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfw387     Document Type: Article

References (73)

1. Ortiz A, Covic A, Fliser D et al. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet 2014; 383: 1831-1843
2. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305
3. United States Renal Data System. 2015 USRDS annual data report: Epidemiology of Kidney Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2015
4. Herzog CA, Asinger RW, Berger AK et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011; 80: 572-586
5. James PA, Oparil S, Carter BL et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507-520
6. Rabar S, Harker M, O'Flynn N et al., Guideline Development Group. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. BMJ 2014; 349: g4356
7. Wanner C, Tonelli M, Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int 2014; 85: 1303-1309
8. Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephro: JASN 2009; 20: 1453-1464
9. Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res 2004; 95: 560-567
10. Fortier C, Mac-Way F, De Serres SA et al. Active vitamin D and accelerated progression of aortic stiffness in hemodialysis patients: a longitudinal observational study. Am J Hyperten 2014; 27: 1346-1354
11. Yilmaz MI, Sonmez A, Saglam M et al. A longitudinal study of inflammation, CKD-mineral bone disorder, and carotid atherosclerosis after renal transplantation. Clin J Am Soc Nephrol 2015; 10: 471-479
12. Barreto DV, Barreto F de C, de Carvalho AB et al. Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study. Am J Kidney Dis 2008; 52: 1139-1150
13. Meneghini M, Regalia A, Alfieri C et al. Calcium and osteoprotegerin levels predict the progression of the abdominal aortic calcifications after kidney transplantation. Transplantation 2013; 96: 42-48
14. Wong MG, Qiang L, Min J et al. Circulating bone morphogenetic protein-7 (BMP7) and transforming growth factor-b1 (TGFb1) as potential biomarkers for renal endpoints in patients with type 2 diabetes mellitus. Nephrology 2011; 16: 24
15. Karakan S, Sezer S, Ozdemir Acar FN et al. Circulating levels of osteopontin are related with calcification parameters in patients with renal transplantations. Transplant Proc 2011; 43: 562-564
16. Bargnoux A-S, Dupuy A-M, Garrigue V et al. Evolution of coronary artery calcifications following kidney transplantation: relationship with osteoprotegerin levels. Am J Transplant 2009; 9: 2571-2579
17. Khan AM, Chirinos JA, Litt H et al. FGF-23 and the progression of coronary arterial calcification in patients new to dialysis. Clin J Am Soc Nephrol 2012; 7: 2017-2022
18. Sharma S, Joseph J, Chonchol M et al. Higher fibroblast growth factor-23 concentrations associate with left ventricular systolic dysfunction in dialysis patients. Clin Nephrol 2013; 80: 313-321
19. Ozkok A, Caliskan Y, Sakaci T et al. Osteoprotegerin/RANKL axis and progression of coronary artery calcification in hemodialysis patients. Clin J Am Soc Nephrol 2012; 7: 965-973
20. Tamei N, Ogawa T, Ishida H et al. Serum fibroblast growth factor-23 levels and progression of aortic arch calcification in non-diabetic patients on chronic hemodialysis. J Atheroscler Thromb 2011; 18: 217-223
21. Cai H, Lu R, Zhang M et al. Serum soluble Klotho level is associated with abdominal aortic calcification in patients on maintenance hemodialysis. Blood Purif 2015; 40: 120-126
22. Ozkok A, Kekik C, Karahan GE et al. FGF-23 associated with the progression of coronary artery calcification in hemodialysis patients. BMC Nephrol 2013; 14: 241
23. Cianciolo G, Capelli I, Angelini ML et al. Importance of vascular calcification in kidney transplant recipients. Am J Nephrol 2014; 39: 418-426
24. Jovanovich A, Chonchol M. Chronic kidney disease: Reductions in FGF-23 levels associated with improved outcomes. Nat Rev Nephrol 2015; 11: 572-573
25. Kovesdy CP. Do FGF23 levels change over time and if yes, what do such changes mean? Nephrol Dial Transplant 2014; 29: 12-14
26. Isakova T. Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease. Curr Opin Nephrol Hypertens 2012; 21: 334-340
27. Kalantar-Zadeh K, Shah A,DuongUet al. Kidney bone disease and mortality in CKD: Revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, andminerals. Kidney Int 2010; 78: S10-S21
28. Chaykovska L, Tsuprykov O, Hocher B. Biomarkers for the prediction of mortality and morbidity in patients with renal replacement therapy. Clin Lab 2011; 57: 455-467
29. Abe M, Okada K, Soma M. Mineral metabolic abnormalities and mortality in dialysis patients. Nutrients 2013; 5: 1002-1023
30. Drüeke TB,Massy ZA. Circulating Klotho levels: Clinical relevance and relationship with tissue Klotho expression. Kidney Int 2013; 83: 13-15
31. Stroup DF, Berlin JA, Morton SC et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012
32. Moher D, Liberati A, Tetzlaff J et al., PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535
33. Wells, GA, Shea, B, O'Connell, B et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Internet]. 2014. Available from: http://www.ohri.ca/programs/clinical-epi demiology/oxford.asp (6 April 2016, date last accessed)
34. Chowdhury R, Kunutsor S, Vitezova A et al. Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies. BMJ 2014; 348: g1903
35. Kunutsor SK, Apekey TA, Seddoh D et al. Liver enzymes and risk of allcause mortality in general populations: a systematic review and meta-analysis. Int J Epidemiol 2014; 43: 187-201
36. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005; 5: 13
37. Higgins JPT, Thompson SG, Deeks JJ et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560
38. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] [Internet]. The Cochrane Collaboration, 2011, Available from: www.handbook.cochrane. org (6 April 2016, date last accessed)
39. Lau J, Ioannidis JPA, Terrin N et al. The case of the misleading funnel plot. BMJ 2006; 333: 597-600
40. Chen X-N, Chen Z-J, Ma X-B et al. Aortic artery and cardiac valve calcification are associated with mortality in Chinese hemodialysis patients: A 3.5 years follow-up. Chin Med J 2015; 128: 2764-2771
41. Chonchol M, Greene T, Zhang Y et al. Low vitamin D and high fibroblast growth factor 23 serum levels associate with infectious and cardiac deaths in the HEMO Study. J AmSoc Nephrol 2016; 27: 227-237
42. Gutierrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl JMed 2008; 359: 584-592
43. Holden RM, Beseau D, Booth SL et al. FGF-23 is associated with cardiac troponin T and mortality in hemodialysis patients. Hemodialysis international. Hemodial Int 2012; 16: 53-58
44. Hsu HJ, Wu M-S. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Am J Med Sci 2009; 337: 116-122
45. Jean G, Terrat J-C, Vanel T et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 2009; 24: 2792-2796
46. Lee JE, Kim HJ,Moon SJ et al. Serum osteoprotegerin is associated with vascular stiffness and the onset of new cardiovascular events in hemodialysis patients. Korean J InternMed 2013; 28: 668-677
47. Montford JR, ChoncholM, Cheung AK et al. Low bodymass index and dyslipidemia in dialysis patients linked to elevated plasma fibroblast growth factor Am J Nephrol 2013; 37: 183-190
48. Morena M, Terrier N, Jaussent I et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol 2006; 17: 262-270
49. Nakashima A, Carrero JJ, Qureshi AR et al. Plasma osteoprotegerin, arterial stiffness, and mortality in normoalbuminemic Japanese hemodialysis patients. Osteoporos Int 2011; 22: 1695-1701
50. Nowak A, Friedrich B, Artunc F et al. Prognostic value and link to atrial fibrillation of soluble klotho and FGF23 in hemodialysis patients. PloS One 2014; 9: e100688
51. Otani-Takei N, Masuda T, Akimoto T et al. Association between serum soluble Klotho levels and mortality in chronic hemodialysis patients. Int J Endocrinol 2015; 2015: 406269
52. Scialla JJ, Kao WHL, Crainiceanu C et al. Biomarkers of vascular calcification and mortality in patients with ESRD. Clin J Am Soc Nephrol 2014; 9: 745-755
53. Scialla JJ, Parekh RS, Eustace JA et al. Race, mineral homeostasis and mortality in patients with end-stage renal disease on dialysis. Am J Nephrol 2015; 42: 25-34
54. Sugimoto H, Ogawa T, Iwabuchi Y et al. Relationship between serum fibroblast growth factor-23 level and mortality in chronic hemodialysis patients. Int Urol Nephrol 2014; 46: 99-106
55. Winther S, Christensen JH, Flyvbjerg A et al. Osteoprotegerin and mortality in hemodialysis patients with cardiovascular disease. Clin Nephrol 2013; 80: 161-167
56. Speer G, Fekete BC, El Hadj Othmane T et al. Serum osteoprotegerin level, carotid-femoral pulse wave velocity and cardiovascular survival in haemodialysis patients. Nephrol Dial Transplant 2008; 23: 3256-3262
57. Baia LC, Humalda JK, Vervloet MG et al. Fibroblast growth factor 23 and cardiovascular mortality after kidney transplantation. Nephrol Dial Transplant 2013; 8: 1968-1978
58. Hjelmesaeth J, Ueland T, Flyvbjerg A et al. Early posttransplant serum osteoprotegerin levels predict long-term (8-year) patient survival and cardiovascular death in renal transplant patients. J Am Soc Nephrol 2006; 17: 1746-1754
59. Svensson M, Dahle DO, Mjøen G et al. Osteoprotegerin as a predictor of renal and cardiovascular outcomes in renal transplant recipients: Follow-up data from the ALERT study. Nephrol Dial Transplant 2012; 27: 2571-2575
60. Wolf M, Molnar MZ, Amaral AP et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011; 22: 956-966
61. Xiao Y, Luo X, Huang W et al. Fibroblast growth factor 23 and risk of allcause mortality and cardiovascular events: a meta-analysis of prospective cohort studies. Int J Cardiol 2014; 174: 824-828
62. Liu S, TangW, Zhou J et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J AmSocNephrol 2006; 17: 1305-1315
63. Shimada T, Kakitani M, Yamazaki Y et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004; 113: 561-568
64. Isakova T, Xie H, Barchi-Chung A et al. Fibroblast growth factor 23 in patients undergoing peritoneal dialysis. Clin J Am Soc Nephrol 2011; 6: 2688-2695
65. Leifheit-Nestler M, Große Siemer R, Flasbart K et al. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease. Nephrol Dial Transplant 2016; 31: 1088-1099
66. Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408
67. Smith ER. The use of fibroblast growth factor 23 testing in patients with kidney disease. Clin J AmSoc Nephrol 2014; 9: 1283-1303
68. Shimada T, Urakawa I, Isakova T et al. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin EndocrinolMetab 2010; 95: 578-585
69. Smith ER, Cai MM, McMahon LP et al. Biological variability of plasma intact and C-terminal FGF23 measurements. J Clin Endocrinol Metab 2012; 97: 3357-3365
70. Tsujita M, Inaguma D, Goto N et al. Beneficial effects of preemptive kidney transplantation on calcium and phosphorus disorders in early posttransplant recipients. Clin Exp Nephrol 2015; 19: 319-324
71. Nybo M, Rasmussen LM. The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. Eur J Endocrinol 2008; 159: 603-608
72. Montanez-Barragan A, Gomez-Barrera I, Sanchez-Nino MD et al. Osteoprotegerin and kidney disease. J Nephrol 2014; 27: 607-617
73. Kiechl S, Werner P, Knoflach M et al. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Expert Rev Cardiovasc Ther 2006; 4: 801-811